|
|
Topic 371 - Phase I SBIR Contract - Valudation and Optimization of RP-185 as Adjuvant to Exploit the Immune Response Generated by Radiation
|
261201800023C
|
$299,847
|
$98,950
|
-, -
|
RIPTIDE BIOSCIENCE, INC.
|
|
|
Topic 375: Novel Diagnostic Imaging Modality for Monitoring Tumor Responses to a Hyperthermia Immunotherapy - Moonshot
|
261201800028C
|
$40,573
|
$13,389
|
-, -
|
IMAGO SYSTEMS, INC.
|
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
$1,182,884
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Preclinical analyses of advanced prostate cancer in genetically-engineered mice
|
2R01CA173481-06
|
$385,883
|
$127,341
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Molecular mechanisms of prostate cancer metastasis
|
5R01CA183929-04
|
$366,000
|
$366,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
|
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages
|
5R01CA172105-04
|
$401,456
|
$401,456
|
ABRAMS, SCOTT
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
$461,172
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-04
|
$2,184,301
|
$1,245,052
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
$256,023
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
$37,125
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
5R03CA219336-02
|
$74,250
|
$37,125
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
|
Analysis of HCC CTC Phenotype for Liver Transplant Candidate Selection
|
1R21CA216807-01A1
|
$203,254
|
$203,254
|
AGOPIAN, VATCHE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
|
Functional Determinants of Metastatic Dormancy
|
5R01CA109182-15
|
$423,844
|
$423,844
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
|
Epigenetic and microenvironmental regulation of dormant disseminated cancer
|
5R01CA218024-02
|
$428,136
|
$214,068
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
$300,000
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
$155,289
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Post-translational control of cancer cell stress response and metastasis
|
5R01CA202027-03
|
$459,505
|
$459,505
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
|
Title: Pre-clinical Evaluation of a Novel Immune Modulator, Alpha-TEA in Combination with Immune Checkpoint Blockade
|
1R43CA228721-01
|
$299,607
|
$149,804
|
AKPORIAYE, EMMANUEL
|
VEANA THERAPEUTICS, LLC
|
|
|
Single-Cell Measurement of Lipid Signaling in Colorectal Cancer
|
5R01CA177993-05
|
$575,397
|
$575,397
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-04
|
$378,171
|
$189,086
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
|
Targeting Tumor Initiating Cell in Undifferentiated Pleomorphic Sarcoma
|
5R01CA183811-05
|
$435,560
|
$108,890
|
ALMAN, BENJAMIN
|
DUKE UNIVERSITY
|
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
$44,174
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
$62,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Novel Molecular Therapies of Prostate Cancer
|
5P01CA140043-09
|
$1,222,825
|
$1,222,825
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
$820,130
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
Tumor Plasticity
|
5R35CA220446-02
|
$1,140,000
|
$1,140,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
|
The Role of LSD1 in the Evolution of Castration Resistant Prostate Cancer
|
5R01CA178610-05
|
$317,240
|
$158,620
|
ALUMKAL, JOSHI
|
OREGON HEALTH & SCIENCE UNIVERSITY
|
|
|
Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence
|
3R01CA208042-03S1
|
$223,893
|
$73,885
|
ALVAREZ, JAMES
|
DUKE UNIVERSITY
|
|
|
Par-4 Regulation and Function in Breast Cancer Dormancy and Recurrence
|
5R01CA208042-03
|
$363,713
|
$120,025
|
ALVAREZ, JAMES
|
DUKE UNIVERSITY
|
|
|
Role of Splicing Factors in Breast Cancer
|
5R00CA178206-05
|
$249,000
|
$249,000
|
ANCZUKOW-CAMARDA, OLGA
|
JACKSON LABORATORY
|
|
|
The regulation of dendritic cell function by LMYC at steady state and during immune responses to cancer
|
1F31CA228240-01
|
$30,442
|
$30,442
|
ANDERSON, DAVID
|
WASHINGTON UNIVERSITY
|
|
|
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance
|
1U01CA232382-01
|
$688,043
|
$227,054
|
ANDERSON, ALEXANDER
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
|
Image guided immunotherapy and targeted radionuclide therapy of metastatic melanoma
|
5R01CA214018-02
|
$481,065
|
$481,065
|
ANDERSON, CAROLYN
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
|
Evaluation of centrosome amplification as a risk-predictor for breast cancer aggr
|
5U01CA179671-05
|
$303,118
|
$303,118
|
ANEJA, RITU
|
GEORGIA STATE UNIVERSITY
|
|
|
Nuclear Factor-kappaB in Ovarian Cancer
|
ZIA BC 011054
|
$480,705
|
$96,141
|
Annunziata, Christina
|
CCR (NCI)
|
|
|
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancer
|
5R01CA196988-02
|
$353,419
|
$353,419
|
ANTALIS, TONI
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
|
Mutant BRAF-regulated transcription factors in melanoma progression
|
5R01CA196278-04
|
$356,850
|
$356,850
|
APLIN, ANDREW
|
THOMAS JEFFERSON UNIVERSITY
|
|
|
Targeting the MET pathway in urothelial carcinoma
|
ZIA BC 011594
|
$497,661
|
$169,205
|
Apolo, Andrea
|
CCR (NCI)
|
|
|
Cerenkov imaging for in vivo pH determination of the tumor microenvironment
|
5F31CA206453-03
|
$31,442
|
$15,721
|
ARROYO PACHECO, ALEJANDRO
|
UNIVERSITY OF PENNSYLVANIA
|
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
$22,367
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
$15,437
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
$300,102
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-09S1
|
$249,371
|
$24,937
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-09
|
$2,480,000
|
$248,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
|
DNA repair alterations in metastatic prostate cancer: functional and therapeutic implications
|
1R01CA230516-01
|
$564,655
|
$564,655
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
$1,113,613
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Cancer Center Support Grant
|
3P30CA082103-19S1
|
$84,000
|
$11,760
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Cancer Center Support Grant
|
3P30CA082103-19S2
|
$206,488
|
$28,908
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Cancer Center Support Grant
|
3P30CA082103-19S3
|
$257,838
|
$36,097
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
|
Targeting Nodal/TGF-Beta pathway to inhibit invasion and growth of retinoblastoma
|
1R21CA229919-01
|
$213,694
|
$106,847
|
ASNAGHI, LAURA
|
JOHNS HOPKINS UNIVERSITY
|
|
Total relevant funding to Metastasis for this search: $448,433,328
|
